CEO's Group Sells Majority Stake, Reducing Beneficial Ownership from 8.2% to 0.5%
Summary
Interim CEO and Chairman Peter Puccetti's group significantly reduced its beneficial ownership in COSCIENS Biopharma Inc. from 8.2% to 0.5% by selling his interest in Goodwood Inc., dissolving a key investor group.
Key Events
-
Significant Reduction in Beneficial Ownership
Peter Puccetti and Puccetti Funds Management Inc. reduced their beneficial ownership in COSCIENS Biopharma Inc. from approximately 8.2% to 0.5% of outstanding common stock.
-
Sale of Goodwood Inc.
The reduction in beneficial ownership stemmed from Peter Puccetti's wholly-owned company selling its equity interest in Goodwood Inc., which managed a fund holding a significant block of COSCIENS shares.
-
Termination of Joint Filing Agreement
The previous joint filing agreement among Peter Puccetti, Goodwood, and Puccetti Funds was terminated, indicating the dissolution of their investor group.
-
Cessation of 5% Ownership
The reporting persons no longer beneficially own more than 5% of the outstanding shares, removing their requirement to file Schedule 13D reports.
Analysis
This Schedule 13D/A reveals a significant reduction in the beneficial ownership of COSCIENS Biopharma Inc. by a group led by Peter Puccetti, who serves as the interim CEO and Chairman. The group's stake plummeted from approximately 8.2% to 0.5% of outstanding shares, effective March 1, 2026. This change resulted from Peter Puccetti's wholly-owned company selling its equity interest in Goodwood Inc., which managed a fund holding a substantial block of COSCIENS shares. While Mr. Puccetti retains his executive roles, this transaction fundamentally alters his financial alignment as a major shareholder and dissolves the previous activist investor group. For a nano-cap company, such a substantial reduction in a key insider's financial stake could be perceived negatively by the market, especially as the company navigates its delisting from NASDAQ and efforts to deregister from the Exchange Act, which were previously disclosed.
At the time of this filing, CSCIF was trading at $2.03 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $0.79 to $4.61. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.